VANCOMICINE RESISTANT ENTEROCOCCUS (VRE): GENERAL PROFILE
DOI:
https://doi.org/10.5281/zenodo.4613828Abstract
The resistant enterococcus (VRE), is known as a multiresistant bacteria as a cause of opportunistic infections and has a great ability to spread into the nosocomial environment. Objective: This literature review aims to clarify pertinent details about hospital infections, more precisely VRE and succinctly VRSA. Methods: This is a review of literature emphasizing the last 9 years, using scientific articles indexed in databases: Lilacs, Bireme, Pubmed and Scielo, in Portuguese, English and Spanish. Several studies were selected with 5% significance. Results: The analyzed studies show the importance of an effective treatment against VRE, since this bacterium spreads easily in hospitals and is difficult to control. Conclusion: the analyzed studies show that hospital infection is a serious problem today, and that treatment needs to be further evaluated and discussed so that there is in fact a control and eradication of multiresistents bacteria.
Downloads
References
- BOUZA E, KESTLER M, BECA T, MARISCAL G, RODRÍGUEZ-CRÉIXEMS M, BERMEJO J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis. Feb 15. 60 (4):528-35. 2015.
- CECI M, DELPECH G, SPARO M, MEZZINA V, SÁNCHEZ BRUNI S, BALDACCINI B. Clinical and microbiological features of bacteremia caused by Enterococcus faecalis. J Infect Dev Ctries. 2015 Nov 30. 9 (11):1195-203.
- CONCEIÇÃO, N et al. Trends in antimicrobial resistance among clinical isolates of enterococci in a brasilian tertiary hospital:a 4- year study. Rev.Soc.Bras.Med.Trop, 44(2), p 177-181, 2011.
- TUON, FF; PENTEADO-FILHO, SR. Controle e tratamento de Enterococcus resistente a vancomicina (VRE). Prática Hospitalar, ano XI, N°62, p.75-80, 2009.
- CARMONA, F et al. Vancomicin – resistant enterococcus outbreak in a pediatric intensive care unit: report of successful interventions for control and prevention. Braz. J. Med. Biol. Res, 45 (2), p 158-162, 2012.
- OLIVEIRA, AC; BETTCHER, L. Aspectos epidemiológicos da ocorrência do Enterococcus resistente a vancomicina, Rev.Esc.Enferm.USP,44 (3),p 725-731, 2009.
- VRANJAC, A. Nota técnica Enterococo resistente a vancomicina (ERV ou VRE), São Paulo, 2009. Disponível em < ftp://ftp.cve.saude.sp.gov.br/doc_tec/ih/NT07_IHENTERO.pdf Acessado dia 30 Ago. 2020.
- ANVISA. Informe técnico nº 05/07 – Surto de Enterococo resistente á Vancomicina em estabelecimentos de Assistência á saúde, Fevereiro 2008.
- ANVISA. Resistência microbiana - Mecansimos e impacto clínico, 2007. Disponível em <http://www.anvisa.gov.br/servicosaude/controle/rede_rm/cursos/rm_controle/opas_web/modulo3/mecanismos.htm,> Acesso em 066 set. 2020.
- ERLANDERSON, KM et al. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients whit vancomycin-resistant Enterococcus bacteremia, C.I.D, 46(1), p 30-36, 2008.
- FERNÁNDEZ-HIDALGO N, ALMIRANTE B, GAVALDÀ J, GURGUI M, PEÑA C, DE ALARCÓN A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013 May. 56(9):1261-8.
- JONES, SB et al. Estudio de factores de riesgo para colonización por enterococco resistente a vancomicina em el hospital militar de Santiago, Rev. Chil. Infect ,26(4), p 374-375, 2009.
- KOBAYASHI, CCBA et al. Resistência antimicrobiana associada em isolados clínicos de Enterococcus spp., Rev.Soc.Bras.Med.Trop, 44(3), p 344-348, 2011.
- KUHNER, D; MARQUES, Á. O desafio do controle da resistência a antimicrobianos nos hospitais, Prática Hospitalar, ano V, N°28, 2003.
- BATISTÃO, DWF et al. Risk factors for vancomicin-resistant enterococci colonization in critically ill patients, Mem.Inst.Oswaldo Cruz, 107(1), p 57-63 2012.
- LUTZ, L; BARTH, AL. Susceptibility of Staphylococcus aureus isolates to vancomicina t a university hospital in southern Brazil, Braz.J.Microbiol, 37(3), p 244-246, 2006.
- MAVE, V et al. Vancomicin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J.Antimicrob.Chemother, 64(1), p 175-180, 2009.
- MORAN GJ, FANG E, COREY GR, DAS AF, DE ANDA C, PROKOCIMER P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Jun 5.
- NIEDERHAUSERN, S et al. Vancomycin-resistance transferability from VanA Enterococci to Sthaphylococcus aureus, Current Microbiology, 62(5), p 1363-1367, 2011.
- ANDERSON AC, JONAS D, HUBER I, KARYGIANNI L, WÖLBER J, HELLWIG E, et al. Enterococcus faecalis from Food, Clinical Specimens, and Oral Sites: Prevalence of Virulence Factors in Association with Biofilm Formation. Front Microbiol. 2015. 6:1534.
- OLIVEIRA, CM. Novas opções terapêuticas para infecções difíceis, CCIH-Santa casa-BH/São Lucas-2011, disponível em < http:// www.hc.UFMG.br/ccih/10_simposio >Acessado em 26 ago 2020.
- PROKOCIMER P, DE ANDA C, FANG E, MEHRA P, DAS A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13. 309(6):559-69.
- RAMASWAMY DP, AMODIO-GROTON M, SCHOLAND SJ. Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series. BMC Urol. 2013 Jul 16. 13(1):33.
- SAKKA V, TSIODRAS S, GALANI L, e al. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect. 2008 Jan. 14(1):14-21.
- SANTOS, AL et al. Sthaphylococcus aureus: visitando uma cepa de importância hospitalar, J.Bras.Patol.Med.Lab, 43(6), p 413-423, 2007.
- SCHMIDT-HIEBER M, BLAU IW, SCHWARTZ S, et al. Intensified strategies to control vancomycin-resistant enterococci in immunocompromised patients. Int J Hematol. 2007 Aug. 86(2):158-62.
- SENNEVILLE E, CAILLON J, CALVET B, JEHL F. Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data. Int J Antimicrob Agents. 2016 Jan. 47 (1):12-9.
- SERVAIS, A. et al. Rapid curbing of a vancomicyn- resistant Enterococcus faecium outbreak in a nephrology department, C.J.A.S.N, 4(10), P 1559-1564, 2009.
- SILVEIRA, GP et al. Estratégias utilizadas no combate a resistência bacteriana, Quim. Nova, 29(4), p. 844-855, 2006.
- SMITH JR, BARBER KE, RAUT A, ABOUTALEB M, SAKOULAS G, RYBAK MJ. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2015. 70 (6):1738-43.
- TALAVERA, G. et al. Colonización intestinal por enterococo resistente a la vancomicina en pacientes oncológicos com factores de riesgo, Pediatr.(Asunción), 38(2), p 123-125, 2011.
- THATI, V; SHIVANNAVAR, TC.; GADDAD, MS. Vancomycin resistance among methicillin resistant Sthapylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad, Indian Journal of medical Research, 134(5),p 704-708, 2011.
- ANVISA. Gram-Positivos, 2008. Disponível em < http://www.anvisa.gov.br/serviçosaude/controle/rede_rm/cursos/boas_praticas/modulo4 > Acesso em 26 set. 2020.
- ARIAS, CA et al. Unmet Needs and prospects for Oritovancin in the Management of Vancomycin- resistant Enterococal Infections, C.I.D, 54(3),p 233-238, 2012.
- ZHANEL, GG.; SCHWEIZER, F; KARLOWSKY, JA. Oritavancin: Mecanismo of Action, C.I.D, 54(3),P 214-219,2012.
